Edwards Evoque TTVR System Evaluated in 2-Year Data From TRISCEND II Trial

April 3, 2026—Edwards Lifesciences announced that 2-year data from the TRISCEND II trial evaluating the company’s Evoque transcatheter tricuspid valve replacement (TTVR) system were presented at ACC.26, the American College of Cardiology’s annual scientific session.

As summarized in Edwards’ press release, the 2-year data demonstrated significant and sustained near elimination of tricuspid regurgitation; improvements in health status and quality of life; no added device-related risk; and significantly lower all-cause mortality when accounting for patient crossover.

“There is a significant patient population suffering with debilitating symptoms from tricuspid regurgitation with very limited treatment options,” commented Vinod Thourani, MD, in the company’s press release. “It’s not a surprise that the sickest patients enrolled in the medical therapy control group of the randomized TRISCEND II trial opted to receive treatment with the Evoque system following the 1-year primary endpoint, underscoring both the benefits of and need for TTVR therapy. Our analyses, including the many highly symptomatic crossover patients, showed significantly improved outcomes for all of the Evoque treated patients.”

The company stated that the new 2-year data expand on the 18-month data of the TRISCEND II trial that were presented last August at ESC 2025, the European Society of Cardiology congress showing achievement of a hard endpoint benefit for the most severe TR patients who received the Evoque therapy, and superior quality of life benefits, regardless of baseline TR.

The Evoque system is approved in both in the United States and Europe, advised Edwards Lifesciences.